^
    8d
    Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=43, Not yet recruiting, Qilu Hospital of Shandong University
    New trial
    |
    Loqtorzi (toripalimab-tpzi) • axitinib
    13d
    SPARCC: A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Stephanie Berg | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    |
    Ibrance (palbociclib) • axitinib • Zumrad (sasanlimab)
    14d
    Unclear territory: navigating metastatic nonclear cell renal cell carcinoma. (PubMed, Curr Opin Oncol)
    Therapeutic advances are reshaping the management of nccRCC, with IO/TKI regimens and histology-specific therapies showing promise. Continued integration of molecular classification, rare subtype-specific trials, and international collaboration will be essential to establish evidence-based treatment standards for this diverse and understudied population.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • FH (Fumarate Hydratase)
    |
    ALK rearrangement
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • erlotinib • Yervoy (ipilimumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • axitinib
    24d
    Potential of Using Cannabidiol as a Therapeutic Molecule Against Various Cell Signaling Molecules Involved in Breast Cancer Complications: A Bioinformatics Approach. (PubMed, Curr Drug Discov Technol)
    CBD demonstrates promising multi-target activity against critical signaling molecules in breast cancer and may serve as a safer, natural therapeutic candidate. Further preclinical and clin-ical investigations are warranted.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDK6 (Cyclin-dependent kinase 6) • MMP2 (Matrix metallopeptidase 2)
    |
    Venclexta (venetoclax) • Ibrance (palbociclib) • axitinib
    25d
    An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=78, Recruiting, Yonsei University
    New P2 trial
    |
    axitinib • SLC-3010
    29d
    Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer. (PubMed, Theranostics)
    Clear cell renal cell carcinoma (ccRCC) is predominantly treated with anti-angiogenic therapies (AATs), such as sunitinib and axitinib. CTGF may thus serve as both a predictive biomarker and a therapeutic target. These findings support further investigation of CTGF inhibition as a strategy to overcome AAT resistance and improve treatment outcomes in ccRCC patients.
    Journal
    |
    CTGF (Connective tissue growth factor)
    |
    sunitinib • axitinib
    1m
    Immuno-molecular features and therapeutic implications of brain metastases in clear cell renal cell carcinoma patients. (PubMed, Genes Immun)
    No partial responses (PR) were observed upon ipilimumab/nivolumab (0%), and pazopanib (0%). PRs were rare upon nivolumab (14%), sunitinib (25%), axitinib (28%) and axitinib/pembrolizumab (33%), but higher upon cabozantinib/nivolumab (50%) and cabozantinib in monotherapy (64%)...Based on this translational and clinical data, cabozantinib is the optimal systemic therapy for m-ccRCC patients with BrM. As the presence of BrM impacts the choice of first-line treatment, we advise to screen for BrM at baseline, even in asymptomatic patients.
    Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • AXL (AXL Receptor Tyrosine Kinase)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • sunitinib • pazopanib • Cabometyx (cabozantinib tablet) • axitinib
    1m
    Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC (clinicaltrials.gov)
    P2, N=75, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Feb 2028 --> Sep 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • axitinib
    1m
    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov)
    P2, N=720, Recruiting, Canadian Cancer Trials Group | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial primary completion date • Tumor mutational burden • Pan tumor
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)
    1m
    Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis (clinicaltrials.gov)
    P2, N=73, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2028 --> Feb 2026 | Trial primary completion date: Jan 2028 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    axitinib
    1m
    Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Columbia University | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    VHL mutation
    |
    axitinib
    1m
    A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST (2024-519176-95-00)
    P1/2, N=58, Completed, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy | Active, not recruiting --> Completed
    Trial completion
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA mutation
    |
    Bavencio (avelumab) • axitinib